A thread for #MECFS, & related, research papers from w/c 1st Feb.
Links will be to our forum discussion threads, where abstracts, links to paper, analysis and discussion can be found. Inclusion in this list does not equal recommendation.
1/11
"ME/CFS: Where Will the Drugs Come From?" by Toogood et al.
"Chronic fatigue syndrome: Abnormally fast muscle fiber conduction in the membranes of motor units at a low-level static force load" by Klaver-Krol et al.
"A Molecular network approach reveals shared cellular and molecular signatures between chronic fatigue syndrome and other fatiguing illnesses" by Comella et al.
"Off label use of Aripiprazole shows promise as a treatment for ME/CFS: a retrospective study of 101 patients treated with a low dose of Aripiprazole" by Bonilla et al.
“Exploratory study into the relationship between the symptoms of chronic fatigue syndrome (CFS)/myalgic encephalomyelitis (ME) and fibromyalgia (FM) using a quasiexperimental design” by Mckay et al.
A thread for #MECFS, & related, research papers from w/c 25th Jan.
Links will be to our forum discussion threads, where abstracts, links to paper, analysis and discussion can be found. Inclusion in this list does not equal recommendation.
1/
"In-Depth Analysis of the Plasma Proteome in ME/CFS Exposes Disrupted Ephrin-Eph and Immune System Signaling" by Hanson et al
A thread for #MECFS, & related, research papers w/c 11th Jan.
Links will be to our forum discussion threads, where abstracts, links to paper, analysis and discussion can be found. Inclusion in this list does not equal recommendation.
1/
"Reversible widespread brain 18F-FDG PET hypometabolism in chronic fatigue syndrome treated by hyperbaric oxygen therapy" by Guedj et al.
Independent re-analysis of the the largest trial that claims benefits of GET and CBT.
"The modest treatment effects obtained on self-report measures in the PACE trial do not exceed what could be reasonably accounted for by participant reporting biases."
A 2017 analysis of patient surveys by @keithgeraghty shows GET is rated negatively by the majority of patients (54%–74%), while pacing "is the most favoured treatment with the lowest negative response rate and the highest reported benefit (44%–82%)."